Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

All-trans Retinoic Acid for Management of Primary Immune Thrombocytopenia : a Randomized, Double-blind, Placebo-controlled Study

NCT07597395 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07597395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07597395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
All-trans Retinoic Acid for Management of Primary Immune Thrombocytopenia : a Randomized, Double-blind, Placebo-controlled Study
Lead sponsor
Peking University People's Hospital
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 30, 2026
Completion date
December 30, 2028
Enrollment
192 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia